TY - JOUR
T1 - Frequent coexistence of RAS mutations in RUNX1-mutated acute myeloid leukemia in Arab Asian children
AU - Al-Kzayer, Lika'a Fasih Y.
AU - Sakashita, Kazuo
AU - Al-Jadiry, Mazin Faisal
AU - Al-Hadad, Salma Abbas
AU - Uyen, Le T.N.
AU - Liu, Tingting
AU - Matsuda, Kazuyuki
AU - Abdulkadhim, Jaafar M.H.
AU - Al-Shujairi, Tariq Abadi
AU - Matti, Zead Ismael I.K.
AU - Hasan, Janan Ghalib
AU - Al-Abdullah, Hussam M.Salih
AU - Inoshita, Toshi
AU - Kamata, Minoru
AU - Sughayer, Maher A.
AU - Madanat, Faris F.
AU - Koike, Kenichi
N1 - Publisher Copyright:
© 2014 Wiley Periodicals, Inc.
PY - 2014/11
Y1 - 2014/11
N2 - Background: RUNX1 mutation plays an important role in adult leukemic transformation. However, its contribution to the development of childhood leukemia remains unclear. In the present study, we analyzed point mutations of RUNX1 gene in children and adolescents with acute myeloid leukemia (AML) from Iraq and Jordan. Procedure: Bone marrow and/or peripheral blood samples were collected from 178 patients of Arab Asian ethnicity (aged ≤17 years) newly diagnosed with AML: 145 samples from Iraq and 33 samples from Jordan. Direct DNA sequencing was performed on six genes including RUNX1 gene (exons 3-8). Results: RUNX1 point mutations were identified in 10 (5.6%) of 178 patients. One patient possessed biallelic mutations of RUNX1 gene. C-terminal area was the predominant site of RUNX1 mutations (eight in C-terminal and two in N-terminal). Patients with RUNX1 mutations were significantly older than those with wild-type of the gene. Additionally, AML M0 subtype was more frequently found in patients with RUNX1 mutations. Both RUNX1 mutations and RAS mutations were identified in 4 of 10 children. Three patients with RUNX1 mutation had FLT3-ITD. On the other hand, 36 (21.4%) and 25 (14.9%) of 168 patients with wild-type of the gene had a RAS mutation and FLT3-ITD, respectively. Eight of 10 patients with RUNX1 mutations died of hematological relapse. Conclusion: The incidence of RUNX1 mutations in Arab Asian children and adolescents with AML was 5.6%. Further studies are required to clarify whether RAS mutations contribute to the development of pediatric AML associated with RUNX1 mutations.
AB - Background: RUNX1 mutation plays an important role in adult leukemic transformation. However, its contribution to the development of childhood leukemia remains unclear. In the present study, we analyzed point mutations of RUNX1 gene in children and adolescents with acute myeloid leukemia (AML) from Iraq and Jordan. Procedure: Bone marrow and/or peripheral blood samples were collected from 178 patients of Arab Asian ethnicity (aged ≤17 years) newly diagnosed with AML: 145 samples from Iraq and 33 samples from Jordan. Direct DNA sequencing was performed on six genes including RUNX1 gene (exons 3-8). Results: RUNX1 point mutations were identified in 10 (5.6%) of 178 patients. One patient possessed biallelic mutations of RUNX1 gene. C-terminal area was the predominant site of RUNX1 mutations (eight in C-terminal and two in N-terminal). Patients with RUNX1 mutations were significantly older than those with wild-type of the gene. Additionally, AML M0 subtype was more frequently found in patients with RUNX1 mutations. Both RUNX1 mutations and RAS mutations were identified in 4 of 10 children. Three patients with RUNX1 mutation had FLT3-ITD. On the other hand, 36 (21.4%) and 25 (14.9%) of 168 patients with wild-type of the gene had a RAS mutation and FLT3-ITD, respectively. Eight of 10 patients with RUNX1 mutations died of hematological relapse. Conclusion: The incidence of RUNX1 mutations in Arab Asian children and adolescents with AML was 5.6%. Further studies are required to clarify whether RAS mutations contribute to the development of pediatric AML associated with RUNX1 mutations.
KW - AML
KW - C-terminal/N-terminal
KW - FTA
KW - MDS
KW - RAS
KW - RUNX1/AML1
UR - https://www.scopus.com/pages/publications/84922652856
U2 - 10.1002/pbc.25151
DO - 10.1002/pbc.25151
M3 - Article
C2 - 25066867
AN - SCOPUS:84922652856
SN - 1545-5009
VL - 61
SP - 1980
EP - 1985
JO - Pediatric Blood & Cancer
JF - Pediatric Blood & Cancer
IS - 11
ER -